At the news
? NEUTRALIMPACT 4/10 144 filed Aug 14, 2026 at 17:47 ET
Atlas Venture, a founding investor in Dyne Therapeutics, filed multiple Form 144 notices on August 14, 2026, signaling intent to sell a combined 322,465 shares of DYN common stock worth approximately $8.4 million. The filing covers two Atlas entities (Opportunity Fund I, L.P. and Fund XI, L.P.) and represents an early-stage venture capital exit. While the dollar amount is modest relative to Dyne's $4.8B market cap, the coordinated sale by a key insider at a time of strong analyst consensus (90% buy/overweight) may signal portfolio rebalancing rather than fundamental concern.
- Atlas Venture Opportunity Fund I, L.P. filed Form 144 for 322,465 shares on August 14, 2026.
- Atlas Venture Fund XI, L.P. also filed Form 144 on the same date for shares of Dyne Therapeutics.
- The estimated aggregate value of the proposed sale is approximately $8.37 million based on a $25.96 reference price.
- Shares were acquired in a private placement on August 7, 2020, a ~6-year hold period.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access